The Val158Met polymorphism in COMT gene and cancer risk: role of endogenous and exogenous catechols.
Catechol-O-methyltransferase, COMT, is an important phase II enzyme catalyzing the transfer of a methyl-group from S-adenosylmethionine to a catechol-containing substrate molecule. A genetic variant Val158Met in the COMT gene leads to a several-fold decrease in the enzymatic activity giving rise to the accumulation of potentially carcinogenic endogenous catechol estrogens and their reactive intermediates and increasing thus the risk of tumorigenesis. However, numerous association studies between the COMT genotype and susceptibility to various malignancies have shown inconsistent and controversial findings indicating that additional gene-gene and gene-environment interactions might be crucial in modulating the physiological role of the COMT. In this review article, the important contribution of dietary catechol-containing flavonoids to modification of the relationships between the COMT genotype and cancer risk is discussed. Whereas, the diverse anticancer activities of common phytochemicals, such as green tea polyphenols, quercetin, fisetin or luteolin, can be markedly changed (both decreased or increased) by the COMT-mediated O-methylation of these exogenous substrates, flavonoids can also behave as potent inhibitors of the COMT enzyme slowing detoxification of endogenous catechol estrogens. Such a many-featured functioning of the COMT and its complex regulation by several different genetic and environmental factors, including plant-based food ingredients, emphasizes the necessity to further stratify the association studies between the COMT genotype and tumor risk by consumption of catechol-containing dietary flavonoids. Currently, it can be only speculated that some of the possible associations might be masked by the regular intake of specific food polyphenols, taking effect in certain communities or populations.
a Department of Hematology and Oncology , Institute of Clinical Medicine, University of Tartu , Tartu , Estonia.
Katrin
K
Sak
D002394:Catechol O-Methyltransferase / Q000235:genetics* / Q000378:metabolism*; D065098:Catechol O-Methyltransferase Inhibitors / Q000494:pharmacology; D002396:Catechols / Q000378:metabolism*; D004032:Diet; D002393:Estrogens, Catechol / Q000009:adverse effects / Q000378:metabolism*; D005419:Flavonoids / Q000494:pharmacology; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics
D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D002393:Estrogens, Catechol; D005419:Flavonoids; D002394:Catechol O-Methyltransferase
Cancer biomarkers; O-methylated flavonoids; catechol estrogens; catechol-O-methyltransferase; dietary flavonoids; phase II metabolism